Community PharmacyProduct News

Clonmel Healthcare Launches International Osteoporosis Awareness Week to celebrate World Osteoporosis Day on 20th October

20th October is World Osteoporosis Day. It was initiated in 1996 by the British Osteoporosis Association with the aim of increasing public awareness of osteoporosis and its prevention. Clonmel Healthcare has extended this to an International Osteoporosis Awareness Week.  From 14th to 20th October 2019, Clonmel Healthcare will provide information on this prevalent disease via social media.

The reason: The incidence of osteoporosis is continually rising. The World Health Organization (WHO) already counts osteoporosis among the ten most frequent chronic diseases of our time. However, the disease is often diagnosed rather late, because osteoporosis can progress inconspicuously for many years. Clonmel Healthcare wants to help those affected and their relatives to better understand the disease and recognise possible symptoms at an early stage.

During the International Osteoporosis Awareness Week, Clonmel Healthcare will be using blog posts and infographics to explain symptoms, risk groups, types of diagnoses and possible prevention and treatment measures.  Three proven treatment approaches for osteoporosis are particularly highlighted: exercise, e.g. gymnastics, whole-food nutrition and drug treatment as long-term therapy over several years. The decision as to which specific measures are suitable for a patient is made by a patient’s GP/Physician depending on the individual case.

Launched in August 2019, Clonmel Healthcare now offers a treatment option in the form of the biosimilar Movymia®. The active ingredient teriparatide contained in the product is used in the therapy of osteoporosis patients. Movymia® is administered via a reusable, multi-dosage injection device; the “Movymia® Pen”. The pen is designed to be used for the entire duration of the treatment.

Other treatment options for Osteoporosis from Clonmel Healthcare include Binosto (Alendronic Acid) 70mg effervescent tablets, which is a buffered alendronate solution. A copy of the SmPC is available upon request or alternatively please go to

Medicinal products subject to medical prescription.

Binosto Once Weekly 70 mg effervescent tablets (PA 126/280/001)

Movymia 20 micrograms/80 microliters solution for injection (EU/1/16/1161/001 – 003)

PA Holder: Clonmel Healthcare Ltd., Clonmel, Co. Tipperary.

Date prepared: October 2019                        2019/ADV/TER/108H

  1. Hodges LA et al. Int Journal of Pharmaceutics 2012;432:57-62.
  2. Invernizzi M et al. Aging Clin Exp Res 2015;27:107-113
Show More

Please Confirm

This website is only for the eyes of medical professionals. Are you a medical professional?